Ironwood Pharmaceuticals
IRWD
138 hedge funds and large institutions have $1.93B invested in Ironwood Pharmaceuticals in 2014 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 48 increasing their positions, 44 reducing their positions, and 21 closing their positions.
21% more call options, than puts
Call options by funds: $14.7M | Put options by funds: $12.1M
19% more capital invested
Capital invested by funds: $1.62B → $1.93B (+$312M)
9% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 44
0% more funds holding
Funds holding: 138 → 138 (0)
0% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 21
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$102M |
| 2 |
TCM
Tamarack Capital Management
Carlsbad,
California
|
+$10.4M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$9.48M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$7.08M |
| 5 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
+$5.53M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$55.6M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$31.9M |
| 3 |
Millennium Management
New York
|
-$25.2M |
| 4 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$20.1M |
| 5 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
-$15.9M |
IRWD Hedge Fund Activity: Q2 2014 in Review
138 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q2 2014, worth a combined $1.93B — up 19% from $1.62B a quarter earlier.
Fund positioning in IRWD was balanced in Q2 2014: 21 funds opened new positions, 21 closed out, 48 added to existing stakes and 44 trimmed.
The largest buyer was OrbiMed, adding an estimated $102M. The largest seller was Sectoral Asset Management, cutting an estimated $55.6M.
- 138 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q2 2014, unchanged from Q1 2014.
- Funds reported $1.93B of Ironwood Pharmaceuticals stock for Q2 2014, up 19% quarter-over-quarter.
- 21 funds opened new Ironwood Pharmaceuticals positions in Q2 2014 and 21 closed out, a net change of 0 holders.
- The largest Ironwood Pharmaceuticals buyer in Q2 2014 was OrbiMed, an estimated $102M added.
- The largest Ironwood Pharmaceuticals seller in Q2 2014 was Sectoral Asset Management, an estimated $55.6M sold.
Based on aggregated 13F filings for Q2 2014.